It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adult-type diffuse glioma (grade 4) has infiltrating nature, and therefore local progression is likely to occur within surrounding non-enhancing T2 hyperintense areas even after gross total resection of contrast-enhancing lesions. Cerebral blood volume (CBV) obtained from dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) is a parameter that is well-known to be a surrogate marker of both histologic and angiographic vascularity in tumors. We built two nnU-Net deep learning models for prediction of early local progression in adult-type diffuse glioma (grade 4), one using conventional MRI alone and one using multiparametric MRI, including conventional MRI and DSC-PWI. Local progression areas were annotated in a non-enhancing T2 hyperintense lesion on preoperative T2 FLAIR images, using the follow-up contrast-enhanced (CE) T1-weighted (T1W) images as the reference standard. The sensitivity was doubled with the addition of nCBV (80% vs. 40%, P = 0.02) while the specificity was decreased nonsignificantly (29% vs. 48%, P = 0.39), suggesting that fewer cases of early local progression would be missed with the addition of nCBV. While the diagnostic performance of CBV model is still poor and needs improving, the multiparametric deep learning model, which presumably learned from the subtle difference in vascularity between early local progression and non-progression voxels within perilesional T2 hyperintensity, may facilitate risk-adapted radiotherapy planning in adult-type diffuse glioma (grade 4) patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Seoul National University College of Medicine, Department of Radiology, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 Seoul National University College of Medicine, Department of Radiology, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University Hospital, Department of Radiology, Seoul, Republic of Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X)
3 Seoul National University College of Medicine, Department of Radiology, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University Hospital, Department of Radiology, Seoul, Republic of Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X); Institute for Basic Science (IBS), Center for Nanoparticle Research, Seoul, Republic of Korea (GRID:grid.410720.0) (ISNI:0000 0004 1784 4496); Seoul National University, School of Chemical and Biological Engineering, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
4 Cancer Research Institute, Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
5 Biomedical Research Institute, Seoul National University College of Medicine, Department of Neurosurgery, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
6 Seoul National University College of Medicine, Department of Pathology, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
7 Cancer Research Institute, Seoul National University College of Medicine, Department of Radiation Oncology, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
8 Seoul National University College of Medicine, Department of Neurology, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
9 Seoul National University Hospital, Department of Radiology, Seoul, Republic of Korea (GRID:grid.412484.f) (ISNI:0000 0001 0302 820X)